Page 1

23 March 2021 Judges Scientific plc ( " Judges Scientific " , " Judges " , the " Company " or the " Group " ) FINAL RESULTS Resilient business model enables sustained execution of strategy with two acquisitions Judges Scientific ( AIM : JDG ) , a group focused on acquiring and developing companies in the scientific instrument sector , announces its final results for the year ended 31 December 2020 . The figures reflect a period during which order intake , revenue and profits were impacted by COVID - 19 . The Group's priority throughout this time has been to ensure the health and safety of its colleagues . Financial Highlights Revenues down 3.2 % to £ 79.9 million ( 2019 : £ 82.5 million ) , including 12.3 % Organic * decline ; Despite COVID - 19 challenges , the Group generated significant profits in every month of 2020 ; Adjusted ** operating profit down 17 % to £ 14.4 million ( 2019 : £ 17.4 million ) ; о Statutory operating profit of £ 10.2 million ( 2019 : £ 14.1 million ) ; Adjusted ** basic earnings per share down 20 % to 177.2p ( 2019 : 222.5p ) ; Statutory basic earnings per share of 131.1p ( 2019 : 183.1p ) ; Final dividend of 38.5p , totalling 55.0p for the year , an increase of 10 % ( excluding 2019 special dividend ) ; covered 3.2 times by adjusted earnings ; Organic * order intake down 13.2 % compared with 2019 ; Organic * order book at 14.0 weeks ( 31 December 2019 : 13.2 weeks ) ; total order book 15.8 weeks ; Cash generated from operations of £ 14.6 million ( 2019 : £ 19.1 million ) ; Adjusted ** net debt of £ 5.7 million as at 31 December 2020 ( 31 December 2019 : £ 2.0 million ) ; о Statutory net debt of £ 5.7 million at 31 December 2020 ( 31 December 2019 : £ 0.3 million ) ; Cash balances of £ 15.5 million as at 31 December 2020 ( 31 December 2019 : £ 14.1 million ) . Strategic Highlights Heath Scientific acquired on 29 May 2020 for a consideration of £ 7.3 million plus excess cash ; Korvus Technology acquired on 19 October 2020 for a consideration of £ 2.6 million plus a potential £ 0.4 million earn - out plus excess cash ; Board strengthened with the appointment of Lushani Kodituwakku as an independent Non - Executive Director . Outlook Effects of pandemic still being felt but signs are positive , and our sector is adapting ; Recovery in order intake still in progress . * Organic describes the performance of the Group including businesses acquired prior to 1 January 2019 . ** Adjusted earnings figures exclude adjusting items relating to amortisation of acquired intangible assets , acquisition - related costs , share based payments and hedging of risks materialising after the end of the year . Adjusted net debt includes acquisition - related liabilities and excludes subordinated debt owed by subsidiaries to non - controlling shareholders . Alex Hambro , Chairman of Judges Scientific , commented : " It was unfortunate that the pandemic interrupted the momentum of our financial progress but I am proud that our businesses took swift , proactive and bespoke action to optimise their performance through this difficult year . I would like to thank our colleagues at every level who worked resolutely to maintain the Group's solid profitability without sacrificing future opportunities . Your Group's resilience has enabled it to continue executing its business model with the completion of two acquisitions and to recommend an increased final dividend for the year . " For further information please contact : Judges Scientific plc David Cicurel , CEO Brad Ormsby , FD Tel : 020 3829 6970 Shore Capital ( Nominated Adviser & Broker ) Stephane Auton Tel : 020 7408 4090 Edward Mansfield